ROIV Stock Analysis: Buy, Sell, or Hold?
ROIV - Roivant Sciences Ltd. Common Shares
$31.26
0.00 (0.02%)
▲
5d:
+4.08%
30d:
+1.21%
90d:
+11.9%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.8/10
Get Alerted When ROIV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ROIV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ROIV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ROIV is currently trading at $31.25, which is considered extended relative to its 30-day fair value range of $28.63 to $30.76.
Technical Outlook: Technically, ROIV is in a uptrend. The price is approaching resistance at $32.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ROIV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.04 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ROIV is in a uptrend. The price is approaching resistance at $32.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ROIV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $39.04 (+24.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.63 -
$30.76
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.9% below Wall St target ($39.04)
Trading Range Analysis
30-Day Trading Range
$28.63 -
$30.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$28.29
Resistance Level
$32.11
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.97
Wall Street Target
$39.04
(+24.9%)
Revenue Growth (YoY)
-66.7%
Earnings Growth (YoY)
-96.1%
Share & Embed Analysis
Last updated: June 23, 2026 11:27 AM ET
Data refreshes hourly during market hours. Next update: 12:27 PM
Data refreshes hourly during market hours. Next update: 12:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ROIV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Venker
SELL
200000 shares
2026-04-20
Matthew Gline
SELL
289774 shares
2026-04-16
Jennifer Humes
SELL
13538 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
Advanced ROIV Option Strategies
Professional options setups generated by AI based on today's ROIV price and gamma walls.
